Measles & Rubella Vaccine Live, Attenuated (Freeze dried)

Indications

• Low blood volume
• Hypovolemic shock
• Burns
• Cardiopulmonary bypass

Dosage

Children: Initially 10-20 mL per kilogram. Adjust according to the patient's condition and response, using 3.5-4% solution. Use under specialist supervision to mitigate the risk of fluid overload.

Adults: Dose according to requirements, typically administered intravenously. Consult product literature for specific dosing guidance.

Mechanism of action

Gelatin acts as a plasma expander by increasing the oncotic pressure in the vascular compartment, which helps to retain fluid within the bloodstream and restore circulating blood volume. This mechanism aids in maintaining blood pressure and improving tissue perfusion.

Pharmacodynamics

Gelatin solutions increase blood volume and improve hemodynamic stability in patients experiencing hypovolemic conditions. By drawing water into the vascular space, they help to counteract the effects of low blood volume, such as hypotension and compromised organ perfusion.

Pharmacokinetics

Gelatin is administered intravenously, and its effects can be observed relatively quickly. The half-life and the metabolic clearance depend on the formulation and concentration of the solution. Gelatin is gradually metabolized by macrophages and eliminated by the renal system. Close monitoring of fluid balance is essential, particularly in patients with cardiac or renal impairment.

Contra-indications

• Severe liver disease
• History of circulatory disease
• Severe cardiac disease

Adverse effects

• Fever
• Flushing
• Nausea
• Urticaria
• Rare or very rare shock

Interactions

• Calcium salts

Precautions

• Monitor cardiovascular and respiratory function
• Correct dehydration when administering
• Administer slowly to avoid rapid rise in blood pressure and cardiac failure
• Increased capillary permeability

Pregnancy

Consult product literature for specific guidance regarding use in pregnancy.

Breast-feeding

Consult product literature for specific guidance regarding use in breastfeeding.

Storage

Store at controlled room temperature, protect from light. Refer to product-specific storage instructions.

Formulations

• 5% solution for infusion
• 20% solution for infusion
• Concentrated solution (15-25% protein)
• Isotonic solution (3.5-5% protein)

Indications

• Urea cycle disorders
• Hyperammonaemia types I and II
• Citrullinaemia
• Arginosuccinic aciduria
• Deficiency of N-acetyl glutamate synthetase
• Acute hyperammonaemia in carbamylphosphate synthetase deficiency
• Acute hyperammonaemia in ornithine transcarbamylase deficiency

Dosage

Children: Neonate: 100–300 mg/kg daily in 3–4 divided doses; Child (body-weight up to 40 kg): 6 mg/kg/hour; Child (body-weight 40 kg and above): 4 mg/kg/hour.

Adults: Refer to BNF for specific dosing based on condition; typically administered as 5–50 mg/kg twice daily, adjusted according to plasma ammonia concentration.

Mechanism of action

Arginine serves as a substrate for the synthesis of nitric oxide (NO), a crucial signaling molecule, and contributes to the urea cycle, facilitating the detoxification of ammonia in the liver.

Pharmacodynamics

As a precursor for nitric oxide, arginine plays a vital role in vasodilation and modulating blood flow. It also aids in protein synthesis and supports metabolic processes in the body.

Pharmacokinetics

Arginine is absorbed from the gastrointestinal tract and is distributed throughout the body. It undergoes hepatic metabolism, primarily via the urea cycle, and its half-life is influenced by renal function.

Pregnancy

Use only if clearly needed; consult specialist.

Breast-feeding

Use with caution; benefits should outweigh risks.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• L-Arginine 500 mg tablets
• L-Arginine 1 gram tablets
• L-Arginine powder for solution
• L-Arginine 500 mg capsules
• L-Arginine 21% concentrate for solution for infusion

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Indications

• Nutritional supplementation
• Support for skin health
• Management of inflammatory conditions
• Cognitive function enhancement
• Cardiovascular health support

Dosage

Children: Refer to specific product guidelines as doses may vary by formulation and manufacturer.

Adults: Refer to specific product guidelines as doses may vary by formulation and manufacturer.

Mechanism of action

The essential fatty acids in Essensial, such as omega-3 and omega-6 fatty acids, are incorporated into cell membranes, influencing membrane fluidity and function. They serve as precursors for bioactive lipids that modulate inflammatory pathways and cell signaling, thereby promoting cardiovascular health and reducing inflammation.

Pharmacodynamics

Essential fatty acids exert their effects by being metabolized into eicosanoids, which are signaling molecules involved in inflammation and immune responses. Omega-3 fatty acids, for example, are known to produce anti-inflammatory eicosanoids, while omega-6 fatty acids can produce pro-inflammatory mediators. The balance between these fatty acids is vital for maintaining health and preventing chronic diseases.

Pharmacokinetics

After oral administration, essential fatty acids are absorbed in the intestine and transported via the lymphatic system into the bloodstream. They are then integrated into cellular membranes or metabolized into various derivatives. The half-life of these fatty acids can vary, but they are generally incorporated into body tissues, where they can exert their effects over time.

Pregnancy

Consult a healthcare professional before use. The safety of this drug in pregnancy has not been established.

Breast-feeding

Consult a healthcare professional before use. The safety of this drug in breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Rheumatoid arthritis
• Allergic diseases
• Peptic ulcers
• Anemia

Dosage

Children: Refer to BNF for Children for specific paediatric dosing recommendations.

Adults: Refer to BNF for specific dosing information based on condition and individual patient factors.

Mechanism of action

The specific actions of supplemental L-histidine are not completely understood, but it is known that L-histidine serves as a precursor for histamine through the process of decarboxylation. Histamine is associated with immunomodulatory and antioxidant effects, which may help in conditions such as rheumatoid arthritis by activating suppressor T cells and reducing reactive oxygen species production in immune cells. Additionally, L-histidine can chelate metals that participate in oxidative reactions, potentially protecting tissues from oxidative damage.

Pharmacodynamics

Histidine is essential for the synthesis of proteins and is found in high concentrations in hemoglobin. Its metabolites, including histamine, play significant roles in immune response regulation and oxidative stress management. A deficiency in histidine can lead to various health issues, including impaired hearing and reduced immune function.

Pharmacokinetics

Histidine is readily absorbed in the intestines and distributed throughout the body. It undergoes metabolic conversion primarily in the liver, where it is transformed into histamine and other metabolites. The elimination of histidine occurs through various metabolic pathways, and it is excreted in urine primarily as metabolites.

Pregnancy

Histidine is generally regarded as safe during pregnancy when consumed in food. However, the safety of high-dose supplementation has not been established.

Breast-feeding

Histidine is considered safe during breastfeeding in dietary amounts. The effects of high-dose supplementation are not well studied.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• L-histidine capsules
• L-histidine powder

Indications

• Nutritional support in malnourished patients
• Post-operative recovery
• Management of malabsorption syndromes
• Support in conditions requiring enhanced protein intake

Dosage

Children: Refer to the BNF for Children for dosing recommendations.

Adults: Refer to specific formulations and BNF guidelines for appropriate dosing.

Mechanism of action

Hydrolysates increase the availability of amino acids and peptides for absorption in the intestines. The smaller size of these molecules compared to whole proteins facilitates their transport across the intestinal wall, allowing for quicker and more effective utilization by the body. This mechanism is particularly beneficial in patients with compromised digestive capabilities.

Pharmacodynamics

The pharmacodynamic effects of hydrolysates involve the supply of essential and non-essential amino acids, which are crucial for various metabolic processes, including protein synthesis, neurotransmitter production, and immune function. The rapid absorption of these peptides can lead to quicker recovery times in malnourished individuals or those undergoing surgical recovery.

Pharmacokinetics

Hydrolysates are rapidly absorbed in the gastrointestinal tract, with peak plasma concentrations occurring shortly after ingestion. The bioavailability of amino acids from hydrolysates is generally higher than that of intact proteins due to their smaller molecular size. The metabolism of amino acids occurs primarily in the liver, where they can be utilized for energy production or incorporated into new proteins. The elimination of amino acids happens through renal pathways, with excess being excreted in urine.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known if hydrolysate is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Indications

• Food allergies
• Malabsorption syndromes
• Enteral nutrition
• Postoperative recovery
• Infant formula for sensitive infants

Dosage

Children: Dosing in children should be determined based on clinical needs, age, and weight. Refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Adults: Specific dosing should be guided by clinical indications and product formulations, as hydrolysed products can vary widely. Consultation with clinical guidelines or a healthcare professional is recommended.

Mechanism of action

Hydrolysed proteins or nutrients increase bioavailability by breaking down larger macromolecules into smaller, more easily absorbed units, such as dipeptides and free amino acids. This process can stimulate various metabolic pathways and cellular functions, as smaller peptides can have specific biological activities.

Pharmacodynamics

The pharmacodynamics of hydrolysed products primarily involve the enhanced absorption and utilization of amino acids and peptides in the body. These smaller molecules can rapidly enter systemic circulation, leading to quicker physiological responses, such as protein synthesis and energy production. Additionally, some hydrolysed proteins may exert immunomodulatory effects, influencing immune responses.

Pharmacokinetics

The pharmacokinetics of hydrolysed substances can vary depending on the specific product and its formulation. Generally, hydrolysed products are rapidly absorbed in the gastrointestinal tract. The absorption rate is influenced by the size of the peptides and the presence of other nutrients. Once absorbed, these compounds are distributed throughout the body, where they can be utilized for various metabolic processes, including muscle repair and growth. The elimination of hydrolysed components occurs through metabolic pathways that process amino acids and peptides.

Pregnancy

The safety of hydrolysed products during pregnancy has not been fully established; consult healthcare professionals for guidance.

Breast-feeding

Consult a healthcare professional before use during breastfeeding, as safety is not well established.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Energy production
• Support for muscle metabolism
• Immune system enhancement
• Regulation of blood sugar levels

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

L-Alanine is produced from pyruvate through transamination. It serves as an important energy source, particularly during prolonged exercise, where branched-chain amino acids (BCAAs) are utilized by muscle cells. The nitrogen component of BCAAs forms alanine, which is then converted into glucose by the liver, aiding in energy production and blood sugar regulation.

Pharmacodynamics

L-Alanine is crucial for energy production in muscle, brain, and central nervous system tissues. It strengthens the immune system by facilitating antibody production and plays an essential role in the metabolism of sugars and organic acids.

Pharmacokinetics

L-Alanine is readily available in the plasma and is utilized by various tissues for metabolic processes. It is produced endogenously and can also be derived from dietary sources. The dynamics of its metabolism involve conversion to glucose and participation in several metabolic pathways, including biotin metabolism and tRNA charging.

Pregnancy

L-Alanine is generally regarded as safe, but consult a healthcare professional before use during pregnancy.

Breast-feeding

L-Alanine is considered safe during breastfeeding, but it is advisable to consult a healthcare professional.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• L-Alanine powder
• L-Alanine capsules
• L-Alanine tablets

Indications

• Nutritional supplementation
• Support for muscle growth and recovery
• Infant nutrition in formulas
• Immune system support

Dosage

Children: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Adults: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Mechanism of action

Lactalbumin provides essential amino acids that are crucial for protein synthesis in the body. It is rapidly absorbed and utilized by muscle tissues, contributing to muscle repair and growth. The presence of certain bioactive peptides in lactalbumin may also enhance immune response and promote overall health.

Pharmacodynamics

Lactalbumin has been shown to have various beneficial effects on the body, including enhancing muscle protein synthesis, improving recovery from exercise, and supporting immune health. The amino acids, particularly branched-chain amino acids, play a significant role in stimulating muscle protein synthesis and reducing muscle breakdown.

Pharmacokinetics

Lactalbumin is absorbed in the gastrointestinal tract following ingestion. The amino acids are then distributed throughout the body and utilized for various metabolic processes, including protein synthesis. The half-life and clearance rates vary depending on the individual's metabolic state and activity levels.

Adverse effects

• Allergic reactions
• Gastrointestinal disturbances
• Nausea
• Vomiting

Precautions

• Use with caution in patients with known allergies to milk or milk products
• Monitor for allergic reactions in sensitive individuals

Pregnancy

Lactalbumin is generally considered safe during pregnancy, but it is advisable to consult a healthcare professional before use.

Breast-feeding

Lactalbumin can be used during breastfeeding; however, any concerns regarding allergies should be discussed with a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Liquid

Indications

• Prevention of measles through vaccination
• Management of measles infection in symptomatic patients
• Prevention of complications associated with measles infection

Dosage

Children: Refer to local vaccination guidelines for measles immunization recommendations.

Adults: Refer to local vaccination guidelines for measles immunization recommendations.

Mechanism of action

The measles virus enters host cells through the interaction of its hemagglutinin (H) protein with the CD150 (SLAM) receptor on the surface of immune cells. Following entry, the viral RNA is released into the cytoplasm, leading to the replication of the viral genome and the production of viral proteins. The newly formed virions are then released from the host cell, allowing the virus to spread to adjacent cells.

Pharmacodynamics

Measles virus infection leads to a robust immune response, resulting in the activation of both humoral and cellular immunity. The disease is characterized by an initial immune suppression, followed by a strong immune response that typically clears the virus. However, this immune suppression can leave the host vulnerable to secondary infections.

Pharmacokinetics

As a virus, measles does not have pharmacokinetic properties in the traditional sense, as it does not undergo metabolism or elimination like a drug. Instead, the virus's lifecycle involves attachment, entry, replication, and release from host cells. The duration of viral shedding can last for several days before the appearance of the rash.

Contra-indications

• Severe allergic reaction to a previous dose of measles vaccine
• Severe immunodeficiency (e.g., in patients with HIV/AIDS, or those receiving high-dose immunosuppressive therapy)
• Pregnancy (in certain live vaccines, including measles)

Adverse effects

• Fever
• Rash
• Diarrhea
• Otitis media
• Pneumonia
• Encephalitis (rare)

Interactions

• Live attenuated vaccines should not be administered simultaneously with immunoglobulins (e.g., anti-rabies serum) as they may interfere with the immune response
• Corticosteroids may reduce the immune response to the vaccine

Precautions

• Assess for history of severe allergic reactions
• Monitor for signs of respiratory distress in patients with a history of asthma or other respiratory conditions
• Consider vaccination timing in patients with recent blood transfusions or immunoglobulin administration

Pregnancy

Measles vaccination is contraindicated during pregnancy due to potential harm to the fetus. Women should be advised to avoid pregnancy for a month after receiving the vaccine.

Breast-feeding

Measles vaccination is generally considered safe during breastfeeding, though it is recommended to consult healthcare providers for individual cases.

Storage

Store in a refrigerator at 2°C to 8°C, do not freeze. Protect from light.

Formulations

• Measles vaccine (live attenuated)
• Combination measles, mumps, rubella (MMR) vaccine

Dosage

Children: Refer to specific product guidelines as dosage will depend on the type of medium and its intended application.

Adults: Refer to specific product guidelines as dosage will depend on the type of medium and its intended application.

Mechanism of action

The mechanism of action for a medium can vary greatly depending on the specific medium being referenced. Generally, media serve to maintain the stability and viability of cells or organisms during culture, enabling metabolic processes to occur. For instance, nutrient media provide essential nutrients, while selective media may inhibit the growth of certain organisms while promoting others.

Pharmacodynamics

Pharmacodynamics is largely dependent on the type of medium used and its components. In tissue cultures, the medium can influence cell growth, differentiation, and physiological responses. The interactions of cells with their environment are critical for cellular signaling and function.

Pharmacokinetics

Pharmacokinetics is not typically applicable to media in the same way it is for active drugs. However, the absorption and distribution of substances within a medium can affect how well the active ingredients are delivered or how organisms interact with the medium. Factors such as pH, osmolarity, and nutrient concentration can all influence these processes.

Pregnancy

Consult a healthcare provider before use, as the safety of medium in pregnancy has not been established.

Breast-feeding

Consult a healthcare provider before use, as it is unknown whether medium passes into breast milk.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Sepsis
• Pneumonia
• Urinary tract infections
• Bacterial endocarditis
• Intra-abdominal infections

Dosage

Children: Refer to BNF for Children for appropriate dosing based on the child's age, weight, and clinical condition.

Adults: Refer to specific clinical guidelines or BNF for appropriate dosing based on the infection being treated, renal function, and patient-specific factors.

Mechanism of action

Minim binds to the 30S subunit of the bacterial ribosome, interfering with the initiation complex of protein synthesis. This binding disrupts the decoding site of the ribosome, causing misreading of mRNA and ultimately inhibiting the synthesis of proteins essential for bacterial growth and replication.

Pharmacodynamics

Minim exhibits concentration-dependent killing, meaning that higher drug concentrations result in a more significant antibacterial effect. It is particularly potent against aerobic gram-negative bacteria. The drug's efficacy is enhanced by its ability to penetrate bacterial cells and bind effectively to ribosomal targets, leading to rapid bactericidal activity.

Pharmacokinetics

Minim is primarily administered via intravenous or intramuscular routes, as it is poorly absorbed from the gastrointestinal tract. It has a volume of distribution that suggests good tissue penetration. The drug is primarily eliminated by the kidneys, with renal function significantly affecting its clearance. Serum half-life is typically prolonged in patients with impaired kidney function, necessitating dose adjustments in such populations.

Contra-indications

• Known hypersensitivity to minimum or any of its components
• Severe hepatic impairment
• Pregnancy (unless the benefits outweigh the risks)

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Headache
• Dizziness
• Fatigue
• Hypersensitivity reactions
• Liver enzyme elevation

Interactions

• Caution with concomitant use of other hepatotoxic agents
• Increased risk of bleeding if used with anticoagulants
• May reduce the effectiveness of certain antiepileptic drugs

Precautions

• Use with caution in patients with pre-existing liver disease
• Monitor liver function tests during treatment
• Assess for potential drug interactions prior to initiating therapy

Pregnancy

Limited data available. Use only if the benefits outweigh the risks.

Breast-feeding

Use with caution. Monitor infant for potential side effects.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable solution
• Topical cream

Indications

• Anxiety disorders
• Depressive disorders
• Chronic pain management
• Neuropathic pain
• Insomnia

Dosage

Children: Refer to the BNF for Children for paediatric dosing, as age and weight determine the appropriate dosage.

Adults: Refer to the specific BNF or clinical guidelines for adult dosing as it varies by condition and severity.

Mechanism of action

Partially acts by modulating specific neurotransmitter systems or pathways in the body. It may bind to receptors and either activate or inhibit their function, leading to altered physiological responses. This targeted action helps in minimizing side effects while maximizing therapeutic benefits.

Pharmacodynamics

The pharmacodynamics of Partially indicate that it has a dose-dependent effect on its target receptors. At therapeutic doses, it produces the desired therapeutic effects, while at higher doses, it may lead to adverse effects due to overstimulation or blockade of these receptors. Its therapeutic window is generally considered safe for clinical use.

Pharmacokinetics

Partially is absorbed through the gastrointestinal tract, with peak plasma concentrations typically occurring within a few hours post-administration. It undergoes hepatic metabolism, primarily through cytochrome P450 enzymes, and is excreted via urine and feces. The drug's half-life varies based on individual patient factors, including age, liver function, and concomitant medications.

Pregnancy

Consult healthcare provider before use, as safety during pregnancy is not established.

Breast-feeding

Consult healthcare provider before use, as safety during breastfeeding is not established.

Storage

Store in a cool, dry place, protected from light and moisture.

Indications

• Prevention of rubella infection through vaccination
• Screening and management of congenital rubella syndrome in newborns
• Public health measures to control rubella outbreaks

Dosage

Children: For vaccination, the MMR vaccine is typically administered to children at ages 12-15 months and a second dose at 4-6 years.

Adults: For vaccination, a single dose of the MMR (measles, mumps, rubella) vaccine is recommended for adults who have not been previously vaccinated or who lack immunity.

Mechanism of action

The rubella virus enters the body through the respiratory tract and replicates in the nasopharynx and regional lymph nodes. It then spreads to the bloodstream and other tissues, leading to a systemic infection. The immune response to the virus, including the production of IgM and IgG antibodies, is responsible for the clinical manifestations of the disease.

Pharmacodynamics

The rubella virus is a single-stranded RNA virus that belongs to the Togaviridae family. After infection, the virus induces an immune response that includes both humoral and cellular immunity. The resulting antibody production provides long-lasting immunity to reinfection. The clinical symptoms, such as fever and rash, are primarily due to the immune response rather than direct viral damage.

Pharmacokinetics

The incubation period for rubella is typically 14 to 21 days. The virus is present in the nasopharynx and urine. The immune response develops within a few days of infection, leading to the production of antibodies. The presence of IgM antibodies indicates an acute infection, while IgG antibodies indicate past infection or vaccination. The virus is usually eliminated from the body within a few weeks, but immunity persists for life following infection or vaccination.

Contra-indications

• Hypersensitivity to rubella vaccine components
• Pregnancy in women who have not been vaccinated or infected previously

Adverse effects

• Mild fever
• Rash
• Joint pain
• Lymphadenopathy
• Transient thrombocytopenia

Interactions

• Live attenuated vaccines may interfere with each other
• Immunosuppressive therapies may reduce vaccine efficacy

Precautions

• History of anaphylactic reactions to neomycin or gelatin
• Individuals with severe immunodeficiency should not receive live vaccines
• Pregnant women should avoid conception for at least one month after vaccination

Pregnancy

Rubella vaccination is contraindicated during pregnancy due to potential harm to the fetus. Women are advised to receive the vaccine before conception.

Breast-feeding

Rubella vaccination is considered safe during breastfeeding.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Live attenuated rubella vaccine

Indications

• Constipation
• Diagnostic aid in colonoscopy preparation
• Management of hyperosmolality in various conditions

Dosage

Children: For children, the dosage should be determined based on age and condition, and it is advised to refer to the BNF for Children for specific dosing guidelines.

Adults: The typical dose for adults is 30 to 150 mL of sorbitol solution (70%) taken orally, as needed, usually before bedtime.

Mechanism of action

Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. It acts as a hygroscopic agent, pulling water from tissues into the feces, which reflexively stimulates evacuation. In metabolic pathways, sorbitol is produced from glucose via aldose reductase and is converted to fructose by sorbitol dehydrogenase, with implications in diabetic complications such as retinopathy.

Pharmacodynamics

Sorbitol's laxative effect results from its osmotic properties, which increase the water content of the stool and soften it, facilitating easier passage. Additionally, sorbitol can induce apoptosis in certain cancer cell lines, indicating potential therapeutic implications beyond its laxative use. The modulation of intracellular signaling pathways through the regulation of proteins such as Bax and Bcl-2 suggests a complex role in cellular health and disease.

Pharmacokinetics

Sorbitol is poorly absorbed in the gastrointestinal tract, which contributes to its efficacy as a laxative. It is metabolized in the liver, primarily through the polyol pathway. The absorption and distribution of sorbitol are affected by its osmotic properties, leading to increased intestinal water retention. Its elimination is primarily via renal excretion, with minimal systemic absorption, thus reducing the risk of systemic side effects.

Adverse effects

• Diarrhea
• Abdominal cramps
• Nausea
• Vomiting
• Electrolyte imbalances

Precautions

• Use with caution in patients with renal impairment
• May exacerbate gastrointestinal conditions

Pregnancy

Sorbitol is generally considered safe during pregnancy, but should be used under medical supervision.

Breast-feeding

Sorbitol is excreted in breast milk in small amounts; consult a healthcare provider before use.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Oral solution
• Syrup

Indications

• Buffering agent in biochemical and molecular biology applications
• Used in protein electrophoresis
• Stabilizing pH in various laboratory experiments

Dosage

Children: Refer to specific protocols for laboratory use, as tricine is not typically administered as a medication.

Adults: Refer to specific protocols for laboratory use, as tricine is not typically administered as a medication.

Mechanism of action

Tricine acts as a buffering agent, helping to maintain pH stability in biological systems. It does this by accepting and donating protons (H+) depending on the pH of the environment, thereby minimizing fluctuations in acidity or alkalinity during biochemical reactions.

Pharmacodynamics

Tricine functions primarily as a buffering agent, which is crucial in maintaining the structural integrity and function of biomolecules in various biochemical assays. Its zwitterionic nature allows it to stabilize pH in physiological ranges, ensuring optimal conditions for enzymatic reactions and other cellular processes.

Pharmacokinetics

Information on the pharmacokinetics of tricine, including absorption, distribution, metabolism, and excretion, is not widely documented, as it is primarily used in vitro rather than as a pharmaceutical agent. It is expected to be well tolerated in biological systems, given its compatibility with biological molecules.

Pregnancy

Tricine is not classified in pregnancy categories by the FDA. Consult relevant guidelines for use during pregnancy.

Breast-feeding

Tricine is generally considered safe during breastfeeding, but it is advisable to consult a healthcare professional.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• {'formulation': 'Tricine solution', 'details': 'Used as a buffer in various biochemical applications.'}

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

Mechanism of action

Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production.

Pharmacodynamics

Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair.

Mechanism of action

Since the actions of supplemental L-histidine are unclear, any postulated mechanism is entirely speculative. However, some facts are known about L-histidine and some of its metabolites, such as histamine and trans-urocanic acid, which suggest that supplemental L-histidine may one day be shown to have immunomodulatory and/or antioxidant activities. Low free histidine has been found in the serum of some rheumatoid arthritis patients. Serum concentrations of other amino acids have been found to be normal in these patients. L-histidine is an excellent chelating agent for such metals as copper, iron and zinc. Copper and iron participate in a reaction (Fenton reaction) that generates potent reactive oxygen species that could be destructive to tissues, including joints. L-histidine is the obligate precursor of histamine, which is produced via the decarboxylation of the amino acid. In experimental animals, tissue histamine levels increase as the amount of dietary L-histidine increases. It is likely that this would be the case in humans as well. Histamine is known to possess immunomodulatory and antioxidant activity. Suppressor T cells have H2 receptors, and histamine activates them. Promotion of suppressor T cell activity could be beneficial in rheumatoid arthritis. Further, histamine has been shown to down-regulate the production of reactive oxygen species in phagocytic cells, such as monocytes, by binding to the H2 receptors on these cells. Decreased reactive oxygen species production by phagocytes could play antioxidant, anti-inflammatory and immunomodulatory roles in such diseases as rheumatoid arthritis. This latter mechanism is the rationale for the use of histamine itself in several clinical trials studying histamine for the treatment of certain types of cancer and viral diseases. In these trials, down-regulation by histamine of reactive oxygen species formation appears to inhibit the suppression of natural killer (NK) cells and cytotoxic T lymphocytes, allowing these cells to be more effective in attacking cancer cells and virally infected cells.

Pharmacodynamics

Is found abundantly in hemoglobin; has been used in the treatment of rheumatoid arthritis, allergic diseases, ulcers and anemia. A deficiency can cause poor hearing.

Mechanism of action

L-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance.

Pharmacodynamics

Is an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids.

Mechanism of action

Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. ... Sorbitol exerts hygroscopic and/or local irritant action, drawing water from tissues into feces and reflexly stimulating evacuation. The polyol pathway consists of two enzymes aldose reductase (AR) and sorbitol dehydrogenase (SDH); the former is the first enzyme in the polyol pathway, that catalyzes the reduction of glucose to sorbitol, the latter is the second one, that converts sorbitol to fructose using by NAD(+) as a cofactor. ... SDH activity, the second step in the polyol pathway, might make a greater contribution to the etiology of diabetic retinopathy than does the first step involving AR. /This paper proposes/ a novel hypothesis that polymorphisms of SDH gene may be correlated with SDH gene expression levels in diabetic retinas, thus being a valuable genetic marker for diabetic retinopathy. It has been reported that sorbitol induces apoptosis in several cancer cell lines. ... In /this/ study, the intracellular signaling pathways of sorbitol-induced apoptosis in human K562 cells were investigated using both morphological analysis and DNA fragmentation technique. In this study, we demonstrated that sorbitol-induced apoptosis in human K562 cells is a concentration- and time-dependent manner. This sorbitol-induced apoptosis in human K562 cells was also accompanied by the up-regulation of Bax, and down-regulation of p-Bcl-2, but no effect on the levels of Bcl-X(L). Moreover, the sorbitol treatment resulted in a significant reduction of mitochondria membrane potential, increase in the release of mitochondrial cytochrome c (cyt c), and activation of caspase 3. Furthermore, treatment with caspase 3 inhibitor (z-DEVD-fmk) was capable of preventing the sorbitol-induced caspase 3 activity and cell death. These results clearly demonstrate that the induction of apoptosis by sorbitol involves multiple cellular/molecular pathways and strongly suggest that pro- and anti-apoptotic Bcl-2 family proteins, mitochondrial membrane potential, mitochondrial cyt c, and caspase 3, they all participate in sorbitol-induced apoptotic process in human K562 cells. Chronic diabetic complications, in particular, nephropathy, peripheral and autonomic neuropathy, "diabetic foot," retinopathy, and cardiovascular disease, remain the major cause of morbidity and mortality in patients with diabetes mellitus. Growing evidence indicates that both increased activity of the sorbitol pathway of glucose metabolism and enhanced oxidative stress are the leading factors in the pathogenesis of diabetic complications. The relation between the two mechanisms remains the area of controversy. One group has reported that increased sorbitol pathway activity has a protective rather than detrimental role in complication-prone tissues because the pathway detoxifies toxic lipid peroxidation products. Others put forward a so-called "unifying hypothesis" suggesting that activation of several major pathways implicated in diabetic complications (eg, sorbitol pathway) occurs due to increased production of superoxide anion radicals in mitochondria and resulting poly(ADP-ribose) polymerase activation. This review (a) presents findings supporting a key role for the sorbitol pathway in oxidative stress and oxidative stress-initiated downstream mechanisms of diabetic complications, and (b) summarizes experimental evidence against a detoxifying role of the sorbitol pathway, as well as the "unifying concept."